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1. Introduction 
Ryanodine receptors (RyRs) are homotetrameric intracellular calcium release channels in the 
membranes of the endoplasmic (ER) and sarcoplasmic reticulum (SR) (George et al. 2005, 
Meissner 2002, 2004). Each subunit consists of ~5000 amino acid residues (George et al. 
2005). There are three isoforms of the ryanodine receptor: the RyR1 isoform is expressed 
predominantly in skeletal muscle, the RyR2 isoform predominates in cardiac muscle, and 
the RyR3 isoform is expressed in a variety of tissues (Sorrentino 1995). In the mammalian 
heart, the RyR2 isoform is a principal component of the excitation-contraction (E-C) 
coupling process. Action potential depolarization of the cardiac cell results in injection of 
calcium ions into the cell via calcium channels (dihydropyridine receptors, DHPRs). This 
small calcium influx then drives the release of calcium from intracellular calcium stores by 
triggering the opening of RyR2 channels (Fabiato 1985). The released calcium causes 
contraction by binding to troponin C (Ebashi and Ogawa 1988). Consequently, precise 
regulation of RyR activity during heartbeat is essential to proper cardiac function. 
In several cardiac diseases, such as heart failure and the genetic diseases CVPT 
(catecholaminergic polymorphic ventricular tachycardia) and ARVD2 (arrhythmogenic right 
ventricular dysplasia), the function of RyR is compromised. In heart failure, the release of 
calcium in response to the action potential is decreased, while RyR remains more active 
during the diastole (Durham et al. 2007, Yano et al. 2006). In CPVT and ARVD2, RyRs 
contain mutations that lead to altered RyR activity which may result in premature calcium 
release in the absence of an action potential (Durham et al. 2007, Yano et al. 2006). 
In this work we present a bioinformatics analysis of the whole of human RyR2 (hRyR2) in 
context with the available functional information, in order to locate individual domains for 
further biochemical and structural studies. The reliability of the predictions in the N-
terminal region (Bauerova-Hlinkova et al. 2010) was verified experimentally by expressing 
and characterizing the domains identified. We also describe the results of a CD-
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spectroscopy study we carried out in order to determine the domain organization of RyR2; 
this study also included an analysis of the secondary structure elements of the N-terminal 
part of RyR2. Finally, we present a homology model of the N-terminal part of RyR2 which is 
based on the recently determined X-ray structure of rabbit RyR1. The amino-acid sequence 
identity of these two proteins is more than 80%, which suggests that predictions made from 
this model will most likely be reliable. The homology model agrees with our bioinformatics 
analysis and also with the results of our CD-spectroscopy study. This model should help to 
locate and identify the mutations and the residues in their proximity that are responsible for 
the cardiac diseases CPVT1 and ARVD2. 
2. Physiological function of RyR2 
Calcium release from intracellular stores is mediated by two types of calcium release 
channels — ryanodine receptors (RyRs) and inositol trisphosphate receptors (IP3Rs) 
(Berridge 1994). These channels are expressed in most tissues. RyRs play a primary role in 
skeletal and cardiac muscle cells, where they mediate muscle contraction. In these tissues 
IP3Rs play only a modulatory role. In contrast, smooth muscle, neurons and non-excitable 
tissues rely on IP3R to play the primary role in calcium release, while RyRs play a 
modulatory role (Berridge 1994). The study of RyRs is therefore mostly concerned with 
understanding their role in the activation of skeletal and cardiac muscle contraction. 
2.1 Ion permeation 
The physiological role of the RyR is to allow permeation of Ca2+ ions from the lumen of the 
SR into the cytosol. Although the calcium gradient between these two compartments is high 
(the diastolic free Ca2+ concentration is only ~100 nM in the cytosol but ~1–2 mM in the SR 
lumen (Shannon et al. 2003)), concentrations of other ions are much larger (~150 mM K+) or 
comparable (~1 mM Mg2+) on both sides of the SR membrane. During the systole, >70% of 
the Ca2+ ions are released from the SR in several milliseconds. Therefore the conductance, 
which determines the rate of transport, and the permeability of the channel for Ca2+ ions, 
which enables selective transport of Ca2+ in the presence of high concentrations of other 
ions, have to be sufficiently high.  
The properties of RyRs have been investigated in planar bilayers by fusion of SR vesicles 
(Meissner and Henderson (1987), reviewed by Meissner (2002)) and by incorporation of 
purified ryanodine receptors (Lai et al. (1988), reviewed by Meissner (2002, 2004)) into 
bilayer membranes. RyRs are characterised by their high conductance and relatively low ion 
selectivity. Their monovalent cation conductance is very high (200–700 pS), highest for the 
RyR2 isoform and lowest for the RyR1 isoform, and they are half-saturated at  
~10–50 mM concentrations for all monovalent cations. Despite their differences in 
conductance, their permeability to all monovalents is approximately equal. The channel is 
6.5-fold more permeable for divalent than for monovalent ions, and their conductance (90–
200 pS) (Williams 1992) increases with the size of the divalent ion. Half-saturation is 
achieved at ~0.5 mM divalent ion concentration, i.e., at much lower concentrations than for 
monovalent ions. These properties of the RyR channel enable effective transport of Ca2+ 
ions. The large conductance ensures a sufficient transport rate, while the high calcium 
affinity ensures that under normal conditions, the rate of Ca2+ transport will be close to 
maximal. The unitary Ca2+ current under physiological conditions has been estimated to be 
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0.4–0.6 pA (Mejia-Alvarez et al. 1999, Kettlun et al. 2003). The permeation properties are 
conferred on the RyR by the amino acids forming the pore, which are close to the C-terminal 
end of the RyR (Du et al. 2001, Zhao et al. 1999), and where aa. GGIG were proposed to form 
the selectivity filter (Balshaw et al. 1999, Gao et al. 2000). 
2.2 Regulation by Ca
2+
  
Ca2+ ions are the most important regulator of RyR activity (Fabiato 1985). They act at several 
Ca2+ binding sites, leading to activation as well as inactivation of RyR. From the 
physiological point of view it is important to note that Mg2+ ions, present at millimolar 
concentrations in the cytosol and the SR lumen, are also capable of binding to all RyR Ca2+ 
binding sites. The existence of two activation sites and two inactivation sites has been 
proposed (Laver 2007, Laver 2009).  
2.2.1 Cytosolic activation  
Cytosolic Ca2+ is the physiological activator of the RyR2 and RyR3 isoforms and contributes 
to the activation of the RyR1 isoform. In the cardiac myocyte, diastolic Ca2+ is ~ 50–100 nM 
(Baartscheer et al. 1998, Kagaya et al. 1995). Ca2+ ions activate RyR channels in the 
concentration range relevant for excitation-contraction coupling (0.3–100 µM). The 
probability that RyR channels are open in the absence of other modulators increases with 
increasing calcium concentration with half-activation at ~1 µM  (Chu et al. 1993, Coronado 
et al. 1994, Gyorke et al. 1994, Meissner 2004, Zahradnikova et al. 1999).  
The time course of both RyR activation (Gyorke and Fill 1993, Schiefer et al. 1995, 
Zahradnikova and Zahradnik 1999, Zahradnikova et al. 1999, Zahradnikova et al. 2003) and 
deactivation (Schiefer et al. 1995, Velez et al. 1997) is very rapid; the activation rate is 
dependent on Ca2+ concentration (Schiefer et al. 1995, Zahradnikova et al. 1999) while the 
deactivation rate is not (Schiefer et al. 1995). The fast activation and deactivation kinetics 
should allow RyRs to respond to physiological calcium signals that last only a few 
milliseconds. The response of the ryanodine receptor to rapid and brief calcium elevations, 
mimicking physiological stimuli, has shown that RyR has several Ca2+ binding sites. In wild-
type RyRs, binding of at least 4 Ca2+ ions precedes channel activation (Zahradnikova et al. 
1999). RyR channels containing subunits mutated in the putative Ca2+ binding sites are less 
sensitive to activation by cytosolic Ca2+ (Li and Chen 2001). Analysis of the calcium 
dependence of RyR tetramers containing both wild-type and mutated monomers confirmed 
the presence of a single Ca2+ binding site on each of the monomers and revealed that 
activation by Ca2+ proceeds by allosteric interaction between Ca2+ binding and channel 
opening (Zahradnik et al. 2005).  The cytosolic Ca2+ binding activation site is located in the 
C-terminal part of the channel (Chen et al. 1998, Li and Chen 2001). The C-terminal part of 
the RyR sequence (amino acids 3661–5037) is capable of forming an ion channel that can be 
activated by calcium (Bhat et al. 1997, Xu et al. 2000). 
Due to competition between Ca2+ and Mg2+ ions, the apparent sensitivity of RyR2 channels 
in situ to activation by calcium is decreased about 10 times by Mg2+ binding to the activation 
site (Meissner 1994). The calcium dependence of in situ RyR activity enabled elucidation of 
the mechanism of the differences between the effect of Mg2+ and Ca2+ on RyR. While 
binding of Ca2+ to the activation site has a strong positively allosteric effect, the binding of 
Mg2+ has a weak negatively allosteric effect (Zahradnikova et al. 2010). At diastolic calcium 
concentrations, more than 75% of the cytosolic activation sites are occupied by Mg2+ 
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(Zahradnikova et al. 2010). Since Mg2+ dissociation from this site is relatively slow 
(Zahradnikova et al. 2003, 2010), it limits the rate at which RyRs can respond to 
physiological Ca2+ elevations, which might play an important role in the physiological 
regulation of RyRs. 
2.2.2 Luminal activation 
Calcium ions also affect RyR activity from the side of the SR lumen. At low cytosolic Ca2+ 
concentrations, when RyR activity is low, the presence of Ca2+ at the luminal side increases 
RyR activity by prolonging channel opening if calcium current flows from the lumen to the 
cytosol, i.e., by binding to the cytosolic calcium binding site (Laver 2007, Laver 2009, Xu and 
Meissner 1998). Luminal Ca2+ also affects RyR activity by binding to a luminal binding site 
which may be located either on the channel or on an associated protein (Gaburjakova and 
Gaburjakova 2006, Gyorke and Gyorke 1998, Gyorke et al. 2004, Qin et al. 2008). The action 
of luminal Ca2+ is complicated by the fact that the SR lumen contains a large amount of 
calsequestrin, a low-affinity Ca2+ buffer, which, in addition to its buffering effect, also 
interacts with RyR and modulates its activity (see below). In planar lipid bilayers, the effect 
of luminal Ca2+ on RyR activity can be explained by a combination of direct binding to the 
luminal activation site and of action at the cytosolic sites via “feed-through” of Ca2+ that 
passes through the channel pore to the cytosolic side of the channel (Laver 2007, 2009). Mg2+ 
inhibits the luminal effect of Ca2+ by competing with it at the luminal activation site (Laver 
and Honen 2008). 
2.2.3 Inactivation 
Their low sensitivity to Ca2+-induced inactivation distinguishes RyR2 and RyR3 from the 
skeletal isoform, which is half-inactivated by ~100 µM Ca2+ (Chu et al. 1993, Lamb 1993, 
Smith et al. 1988). The identity of the inactivating calcium binding site is unknown. Because 
of the differences between RyR1 on one hand and RyR2/RyR3 on the other, it is assumed 
that the differences in sensitivity to calcium-dependent inactivation may be partially due to 
the divergent region DR1, which differs between these RyR isoforms (Du et al. 2000). The 
inhibitory site has low specificity—the affinity of Mg2+ and Ca2+ to this binding site is 
similar (Gyorke and Gyorke 1998, Laver and Honen 2008, Laver et al. 1997, Xu et al. 1996). 
2.2.4 Activation by ATP  
ATP increases the probability that the RyR channel will be open (EC50 = ~100 µM) without 
markedly affecting its calcium dependence (Xu et al. 1996). The activity of the RyR1 isoform 
is potentiated more strongly than that of RyR2 (Zimanyi and Pessah 1991). Although most 
ATP in the cell is present in the form of Mg·ATP, it seems that the activating species is free 
ATP2- (Copello et al. 2002). Other nucleosides are much less effective than ATP. ADP is a 
partial agonist with a lower affinity (EC50 = ~1 mM). Adenosine and adenine have a still 
lower effect. CTP, GTP, ITP and UTP do not activate the channel at all (Meissner 2002). The 
existence of the adenine ring is necessary for ATP binding, and the large effectiveness of 
channel activation by ATP appears to be caused by the presence of the negatively charged 
phosphate groups (Chan et al. 2000, 2003). 
2.2.5 Modulation by associated proteins 
Calmodulin (CaM) is a small Ca2+-binding protein that affects many enzymes, receptors and 
channels. CaM with four bound calcium ions and apo-CaM without bound Ca2+ ions have 
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different conformations and therefore also different effects. CaM inhibits all RyR isoforms. 
Apo-CaM has a stimulatory effect on the activity of RyR1 and RyR3, but, depending on 
conditions, it either does not affect or inhibits the RyR2 isoform. The effects of CaM are 
mediated by its high-affinity binding to a binding site (amino acids 3583–3603 in RyR2) on 
each of the monomers, which is conserved in all RyR isoforms. The different CaM effects on 
the different isoforms are apparently due to differences in the isoforms in a region outside 
the CaM binding site (Meissner 2004). The locations of bound CaM and apo-CaM on the 
binding site are different (Meissner 2004), and a calcium-dependent physical relocation of 
CaM on the RyR molecule has also been observed by cryoelectron microscopy (cryo-EM) 
(Samso and Wagenknecht 2002). Modulation of RyR activity by calmodulin may therefore 
involve conformational changes in more distant parts of the RyR protein.  
FKBP (FK506-binding protein) belongs to the immunophilins, cytosolic receptors for 
imunosuppresants such as rapamycin and FK506. Each RyR monomer contains a binding 
site for either FKBP12 (in RyR1) or FKBP12.6 (in RyR2). The interaction of FKBP with the 
channel stabilizes the protein complex and supports coordinated gating of all four subunits. 
It is thought that FKBP also plays a role in coupled gating of neighbouring RyR channels 
(Williams et al. 2001).  
In addition to RyR channels, the SR membrane of terminal cisternae also contains the 
proteins triadin and junctin (Bers 2004) which associate with RyRs from the luminal side. In 
the lumen of the terminal cisterna there is also a large quantity of the protein calsequestrin 
(CSQ), a low-affinity calcium-binding protein that serves as a calcium buffer and also 
modulates RyR activity in a calcium-dependent manner (Bers 2004). CSQ most probably 
interacts with the RyR channel through interactions with triadin and junctin, so that for 
correct luminal regulation all three accessory proteins are necessary (Gyorke et al. 2004, 
Terentyev et al. 2008). 
2.2.6 Modulation by phosphorylation 
Ryanodine receptors have several conserved regions that are putative phosphorylation sites. 
Furthermore, kinases (PKA) and phosphatases (PP1 and PP2A) are directly attached to the 
channel, suggesting that regulation by phosphorylation may have physiological significance 
(Marx et al. 2001). The first phosphorylation site discovered on the RyR2 molecule (Witcher 
et al. 1991) was S2809 (S2843 in RyR1), which can be phosphorylated by the 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) and to some extent also by PKA. 
Other kinases, such as PKG and PKC, affect RyRs as well (Takasago et al. 1991), e.g. by 
changing their ability to bind the alkaloid ryanodine. The mechanisms by which 
phosphorylation and dephosphorylation induce changes in RyR activity are not clearly 
understood, however. An increase in RyR activity due to an increase in calcium sensitivity 
(Marx and Marks 2002), as well as an increase in the rate of adaptation after a rapid calcium 
increase (Valdivia et al. 1995) have both been observed after phosphorylation. 
2.2.7 Interdomain interactions 
Most of the mutations that affect RyR2 function in CPVT and ARVD2 are located in either of 
four domains: the N-terminal domain, the central domain, the cytoplasmic I-domain, and 
the transmembrane domain. This clustering, as well as the similarity between the effects of 
mutations at different positions within these domains (hyperactivation of the channel and 
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increased sensitivity to agonists) led to the postulation of the interdomain hypothesis 
(Yamamoto et al. 2000). It was hypothesized that there is an interaction between the N-
terminal and the central domain that stabilizes the channel in the closed state. Mutations 
within these domains would then weaken this interdomain interaction (Ikemoto and 
Yamamoto 2000, Yamamoto et al. 2000) and these changes might play a key role in the 
regulatory mechanisms of the channel. The experimental strategy to test this hypothesis was 
based on the assumption that if an interaction between two regions functions as a regulatory 
mechanism, then a synthetic domain peptide with a sequence identical to that of one of the 
interacting regions should destabilize the interaction and disturb RyR regulation in a way 
similar to that observed in the mutations. Several domain peptides from the N-terminal and 
central region of RyR1 or RyR2 (H163–S195, L590–C609 and L601–C620, L2442–P2477 and 
G2460–P2495, D2380–A2411) were indeed able to activate RyR and increase its sensitivity to 
agonists (El-Hayek et al. 1999, Faltinova et al. 2011, Tateishi et al. 2009, Yamamoto and 
Ikemoto 2002, Yang et al. 2006). The group of Yamamoto and Ikemoto further postulated, 
based results of George et al. (2004), that the interaction between the I-domain and another, 
undefined domain also plays a role in stabilizing the closed state of RyR2. A domain peptide 
from the I-domain (P4090–E4123) did indeed activate RyR2 (Tateishi et al. 2009). 
Furthermore, mutations in the N-terminal and central domains destabilized the interaction 
of RyR2 with its regulator calmodulin (Ono et al. 2010). Two RyR-stabilizing drugs that act 
on the central (K201) and N-terminal domains (dantrolene) antagonized the effect of the 
central and N-terminal mutations, respectively, and restored calmodulin binding (Ono et al. 
2010, Xu et al. 2010). Transmission between the interdomain interaction, calmodulin 
binding, and channel opening is believed to be mediated by a calmodulin-like domain 
(residues 4064–4210 in RyR1; (Xiong et al. 2006)) and its interaction with the calmodulin 
binding domain of RyR (Ono et al. 2010). The effect of CPVT and ARVD2 mutations on the 
extent of interdomain interaction may be manifested as a change in the intrinsic opening 
tendency of the channel or in the allosteric effect between calcium binding and channel 
opening (Zahradnikova et al. 2010). 
2.3 Excitation-contraction coupling 
The RyRs are located at tubulo-reticular junctions, special calcium release sites, where they 
face the adjacent calcium channels (DHPRs) of the plasma membrane. The release sites in 
both skeletal and cardiac muscle contain clusters of RyRs and DHPRs, and their structures 
are quite similar. However, DHPRs and RyRs are positioned very precisely adjacent to one 
another in skeletal muscle but not in cardiac muscle (Protasi 2002). Therefore, in contrast to 
skeletal muscle, where RyR1 is activated by conformational changes in the DHPR protein 
(Rios and Brum 1987, Rios et al. 1993), in cardiac cells RyRs are activated by calcium ions 
that flow into the dyadic space during single-channel openings of DHPRs (Fabiato 1985).  
Calcium sparks, calcium release events of individual calcium release units (Cheng et al. 
1993), raise local cytosolic Ca2+ concentrations by 200 nM (Cannell et al. 1994, Cannell et al. 
1995, Cheng et al. 1993, Lopez-Lopez et al. 1995). They can be discerned when release 
probability is low (Cheng et al. 1993). Although the probability of spontaneous sparks in a 
rat ventricular myocyte is low (about 100 s-1) (Cheng et al. 1993), openings of L-type Ca2+ 
channels greatly increase this probability during a voltage step depolarization (Cannell et al. 
1995, Lopez-Lopez et al. 1995).  Ca2+ sparks are stereotypical, i.e., their amplitudes and 
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spatio-temporal properties appear to be independent of their trigger signal (Cannell et al. 
1995, Lopez-Lopez et al. 1995). This indicates that the amplitude and time course of a Ca2+ 
spark is largely governed by the properties of the participating RyRs. Thus, Ca2+ sparks can 
be considered to be the elementary Ca2+ release events underlying E-C coupling, and 
gradation of calcium release in response to ICa can be explained by the summation of 
variable numbers of Ca2+ sparks being activated (Cheng et al. 1996).  
Under normal conditions, Ca2+ sparks are unable to activate additional Ca2+ sparks in 
adjacent regions, although the local free Ca2+ concentration associated with a Ca2+ spark is 
much larger than the global increase in free Ca2+ concentration produced by Ca2+ current 
activation ((Cannell et al. 1995), but see Parker et al. (1996)). This observation can be 
explained by the fact that SR Ca2+ release channels are situated very close to the L-type Ca2+ 
channel (the “local control model”; (Stern 1992)), where they sense the > 100-fold increase in 
local free Ca2+ concentration upon opening of a nearby L-type Ca2+ channel. The sensitivity 
of this local control is most clearly seen in the evidence that a single DHPR channel opening 
can elicit a Ca2+ spark (Cannell et al. 1995, Lopez-Lopez et al. 1995, Santana et al. 1996). A 
detailed analysis revealed that the probability of Ca2+ activation depends on the square of 
the single sarcolemmal Ca2+ channel current and on the square of the local free Ca2+ 
concentration (Santana et al. 1996) and that it is quite sensitive to the duration of the DPHR 
openings (Zahradnikova et al. 1999). Theoretical calculations (Cannell and Soeller 1997) as 
well as experimental data (Zahradnikova et al. 1999) suggest that RyRs can respond rapidly 
to calcium influx via DHPRs; the responsiveness of RyRs in situ depends on the geometrical 
arrangement of channels in the narrow dyadic space, in which high Ca2+ levels rapidly 
develop near the SR membrane. Such high Ca2+ levels lead to a rapid rate of binding of 
calcium to the RyR calcium sensitive sites, thereby reducing the latency between DHPR 
opening and SR calcium release to ~1 ms, in correspondence with the experimentally 
observed DHPR mean open times. However, direct measurements of the latency between 
long (~20-ms) calcium channel openings and spark activation (Wang et al. 2001) indicated a 
much longer latency (~7 ms). Since the binding of Mg2+ (Zahradnikova et al. 2010, 
Zahradnikova et al. 2003) has not been included in the model (Cannell and Soeller 1997), it 
may be inferred that only RyR channels that do not have Mg2+ bound are able to respond 
rapidly to DHPR openings (Zahradnikova et al. 2010, Zahradnikova et al. 2003). 
It is not clear how many RyR channels contribute to a Ca2+ spark. While there are 5-9 RyRs 
per DHPR in cardiac myocytes, individual Ca2+ sparks may reflect activation of up to 20 
RyRs (Bridge et al. 1999, Lukyanenko et al. 2000). This means that the majority of RyRs are 
activated by neighbouring RyRs and not by adjacent DHPR channels. A quantitative model 
of spark activation based on the allosteric action of Ca2+ and Mg2+ on RyR2 opening 
(Zahradnikova et al. 2010) predicts the opening of 1–8 RyR2 channels per spark, in 
agreement with experimental findings (Wang et al. 2001).   
3. Structure of ryanodine receptors 
3.1 Overall structural features determined by cryoelectron microscopy (cryo-EM)  
RyR channels are the largest ion channels known so far, which makes structural studies of 
them very challenging. So far, the structure of a whole RyR has been determined only by 
cryo-EM. Most of these studies, including sub-nanometer EM (Samso et al. 2009, 
 
Bioinformatics – Trends and Methodologies 
 
332 
Serysheva et al. 2008) have focused on the skeletal RyR1 isoform, but some studies have 
been performed on RyR2 (Liu et al. 2002, Sharma et al. 1998) and RyR3 (Liu et al. 2001, 
Sharma et al. 2000) as well. In agreement with the high sequence homology of RyRs, 
which reaches ~65%, EM structures of all three isoforms are very similar (Wagenknecht 
and Samso 2002). The RyR2 (Sharma et al. 1998) and RyR3 (Sharma et al. 2000) isoforms 
differ slightly from the RyR1 isoform in several structural domains (called divergent 
regions) that map to segments of reduced homology between the RyR isoforms (Zhang et 
al. 2003), though the overall structure of the RyR isoforms is very well conserved 
(Wagenknecht and Samso 2002). The complete channel is made from a combination of 
four monomers to yield a tetramer with a fourfold axis of symmetry. The divergent 
regions have been suggested to play a role in calcium-dependent inactivation (DR1) (Du 
and Maclennan 1999), in signal transmission between DHPR and RyR1 (DR2) (Perez et al. 
2003), and in conformational changes of the RyR and RyR-RyR interactions (DR3) (Zhang 
et al. 2003).  
Each subunit of the RyR homotetramer consists of two main parts: a cytoplasmic part and a 
transmembrane part. The cytoplasmic part of the whole receptor, also called the “foot”, is 
very large (280 × 280 × 120 Å) and interacts with many modulators which affect channel 
gating (Yano et al. 2006). It is composed of several structural segments: the clamp and the 
handle at the perimeter, the central rim surrounding the putative pore, and the column 
connecting the cytoplasmic and transmembrane parts (Fig. 1). These segments have been 
further subdivided into 15 subdomains (Lanner et al. 2010). The clamps are located at the 
corners of the cytoplasmic part and are likely to participate in intermolecular interactions 
with neighboring RyR molecules and other RyR modulators. They undergo large changes 
during the opening and closing of the channel (Orlova et al. 1996, Samso et al. 2009, 
Serysheva et al. 1999). Like the cytoplasmic domain, the transmembrane part undergoes 
large structural changes during the opening and closing of the RyR2 channel (Orlova et al. 
1996, Samso et al. 2009, Serysheva et al. 1999). 
3.2 Bioinformatics domain prediction 
To find the putative individual structural entities of hRyR2, we analyzed the whole hRyR2 
amino acid sequence using the PFAM domain database (Finn et al. 2008). Fourteen probable 
domains were found in the hRyR2 monomer. Eight of them are located in the N-terminal 
region (residues 1–~1561) and were identified as Ins145_P3_rec, MIR, RIH, SPRY and two 
RyR domains. The central region (residues 1562–3000) contains the RIH domain and two 
RyR domains. The C-terminal part (residues 3001–4995) contains an RIH associated domain, 
a RR_TM4-6 domain and an Ion_Trans domain, Fig. 2. The beginnings and ends of each 
domain are numbered according to the PFAM search results. Mutations of specific residues 
involved in ARVD2 and CPVT1 are shown (Yano et al. 2006; www.fsm.it/cardmoc). LIZ1-3 
(amino acid residues 554–585, 1603–1631, and 3003–3039) represent leucine-isoleucine zipper 
areas. The proposed binding partners, SPI, PR130, mKAP, PP1, PP2A, PKA, D, K201, FKBP, 
and CaM represent spinophilin, protein 130, muscle specific kinase anchoring protein, 
protein phosphatases 1 and 2A, protein kinase A, dantrolene, 1,4-benzothiazepine derivative 
K201 (JTV519), FK-binding protein, and calmodulin, respectively. Binding partners for 
hRyR2 and their positions were adapted from Wang et al. (2011), Yamamoto et al. (2008), 
and Yano et al. (2006).  
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Fig. 1. A cryo-EM density map of RyR1 (accession no. 1274, http://www.ebi.ac.uk/emdb-
srv/atlas/1274_summary.html) in the in closed state. A. Cytopasmic view. B. Side view. The 
cytoplasmic (clamp, handle, central rim and column) and transmembrane regions (TM) are 
indicated.   
 
Fig. 2. Analysis of the human cardiac ryanodine receptor using the PFAM database. The 
position and type of mutations resulting in CVPT or ARVD2, as reported at 
www.fsm.it/cardmoc/, are indicated above the sequence regions.  
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3.3 X-ray analysis 
To date, X-ray structures have been determined for several N-terminal fragments of rabbit 
RyR1 (residues ~12–210 (Amador et al. 2009, Lobo and Van Petegem 2009); residues 12–532 
(Tung et al. 2010)); and murine RyR2 (residues 12–217, wt and mutants A77V and V186M) 
(Lobo and Van Petegem 2009). The overall structures of all isoforms, including those 
containing mutations, are very similar (superposition results in r.m.s.d. of 0.69 Å for 150 Cα 
atoms), Fig. 3, which is not surprising due to their close sequence homology and 
physiological function. The longest fragment, residues 12–532, is composed of three 
structural domains, which have been designated as A (1–205), B (206–394) and C (395–532) 
(Tung et al. 2010). Domains B and C are homologous respectively with the -trefoil and -
helical domains of the IP3R binding core. Domain A is homologous with the IP3 binding 
suppressor domain of IP3R (Yuchi and Van Petegem 2011). The central motif of domains A 
and B is a -trefoil core consisting of 12 -strands which are held together by hydrophobic 
interactions. In the A domain, a 10-residue -helix is inserted between strands 4 and 5 
(Lobo and Van Petegem 2009). Domain C consists of five -helices. Most of the secondary 
structure elements are connected by flexible loops, which were proposed to be located at the 
interfaces with other RyR domains or at the interfaces with proteins interacting with RyR 
(Tung et al. 2010, Yano et al. 2006). The X-ray crystal structures allowed the precise mapping 
of several mutations which are associated with CPVT and ARVD2 (Lobo and Van Petegem 
2009), as well as the homologous mutations in RyR1 which are responsible for malignant 
hyperthermia (MH) and central core disease (CCD) (Tung et al. 2010). 
 
 
Fig. 3. Comparison of X-ray structures of the N-terminal domains of RyR1 (PDB ID 2XOA 
green, 3HSM pink, 3ILA magenta) and RyR2 (PDB ID 3IM5 blue, 3IM6 yellow, 3IM7 
purple). The superposition was performed using the program Multiprot (Shatsky et al. 
2004), through 150 Cα atoms with a r.m.s.d. of 0.69 Å. Arrows indicate flexible loops. 
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3.4 Relationships between domain structure, 3D structure and RyR function 
3.4.1 The Ins145_P3_rec domain 
The Ins145_P3_rec domain is found in RyRs and IP3Rs (Ponting C. P. 2000). In IP3R, it 
participates in forming the ligand binding suppressor region (Bosanac et al. 2005). In the 
structure of RyR1, it is equivalent to the first N-terminal domain A (Tung et al. 2010). The 
PFAM prediction assigned this domain to residues 9–223, while in the RyR1 structure it 
corresponds to the equivalent RyR2 amino acids 12–228. This domain contains two closely 
spaced clusters of mutations associated with CPVT and ARVD in the region of residues 62–
81 and 164–189 (http://www.fsm.it/cardmoc), which belong to the first mutation cluster 
CPVT-I (George et al. 2007). The domain consists of 12 -strands, arranged into a -trefoil 
motif (see below). Superposing the ligand-binding suppressor domain of the IP3R (PDB ID 
1XZZ; (Serysheva et al. 2008)) and the X-ray structure of the N-terminal portion of RyR1 into 
the cryo-EM density map of RyR1 (Tung et al. 2010) indicates that this domain should lie in 
the clamp or on the central rim of the ion channel, respectively. 
3.4.2 The MIR domain 
MIR domains are found in a number of proteins (George et al. 2007, Hamada et al. 1996, 
Strahl-Bolsinger and Scheinost 1999), including IP3Rs (Bosanac et al. 2005, Bosanac et al. 
2002), and RyRs (Amador et al. 2009, Lobo and Van Petegem 2009, Ponting 2000, Tung et al. 
2010). They usually consist of several ~50-residue MIR motifs with a β-trefoil fold (Murzin et 
al. 1992), and form β-barrel structures with hairpin triplets and internal pseudo-threefold 
symmetry (Bosanac et al. 2005). In RyR1, the MIR domain is equivalent to the second N-
terminal domain, domain B (Tung et al. 2010). In PMT1 mannosyltransferases, MIR motifs 
are located in the luminal loops of the enzyme and are essential for transferase activity 
(Stahl-Bolsinger et al., 1999). In IP3R, the first two of the β-trefoil motifs were found to 
belong to the suppressor region (Ins145_P3_rec, (Bosanac et al. 2002), see above), while the 
latter two (parts of the MIR domain) belong to the ligand binding region (Bosanac et al. 
2005). Similar β-trefoil motifs were predicted to be present in the N-terminal region of the 
RyR1 isoform (Bosanac et al. 2002), and were later found in its crystal structure (Amador et 
al. 2009), although the sequence similarity between IP3R and RyR is relatively low. PFAM 
predicted this domain to lie between residues 226–406 of RyR2, and in the RyR1 structure it 
corresponds to the equivalent RyR2 amino acids 228–411. This region contains a large 
number of CPVT/ARVD2 mutations (Fig. 2) (http://www.fsm.it/cardmoc/), which belong 
to the first mutation cluster CPVT-I (George et al. 2007). Docking of the ligand-binding 
domain of IP3R (PDB ID 1N4K, (Serysheva et al. 2005); PDB ID 1XZZ and PDB ID 1N4K, 
(Serysheva et al. 2008)) into the cryo-EM structure of RyR1 predicts that this domain will lie 
in the clamp region while doing a similar docking using the X-ray structure of the N-
terminal sequence of RyR1 (Tung et al. 2010) indicates that the MIR domain should lie on 
the central rim.  
3.4.3 The RIH domains 
Two RIH domains were found in both RyRs and IP3Rs. The X-ray structure of a major part 
of the first RIH domain of both IP3R (Bosanac et al. 2002) and RyR1 (Tung et al. 2010) has 
been determined. In the case of RyR1, this corresponds to domain C and the structure 
extends out to residue 532, which corresponds to residue 543 in hRyR2. Structurally, RIH is 
composed of -helices. In IP3R, this domain forms the binding site for inositol 1,4,5-
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trisphosphate (Bosanac et al. 2002). By superposing the ligand suppressor domain (PDB ID 
1XZZ) and the ligand binding core (PDB ID 1N4K) on the N-terminal part of RyR1 (PDB ID 
2XAO), it was proposed that all three domains of IP3R, i.e. Ins145_P3_rec, MIR and RIH, 
interact together, as predicted by Chan et al. (2007), and are arranged similarly as in the N-
terminal part of RyR1 (Yuchi and Van Petegem 2011). The PFAM prediction placed this 
domain between residues 451–655, while in the RyR1 structure its beginning corresponds to 
the equivalent RyR2 amino acid 410. In RyR2, the RIH domain was reported to contain a 
leucine–isoleucine zipper between amino acid residues 554 and 585 that mediates binding of 
the phosphatase PP1 via the spinophilin targeting protein (Marx et al. 2001). This domain 
was also proposed to contain the binding site for dantrolene (residue 626 in hRyR2), and it 
contains several of the CPVT/ARVD2 mutations (http://www.fsm.it/cardmoc/), which 
belong to the first mutation cluster CPVT-I (George et al. 2007). It was located in the clamp 
region by cryo-EM (Wang et al. 2011). However, docking of the X-ray structure of the N-
terminal sequence of RyR1 into the cryo-EM structure of RyR1 predicts that this domain lies 
in the central rim (Tung et al. 2010). 
PFAM predicted that the second RIH domain lies between residues 2121-2332. This domain 
and its C-terminally adjacent region contain the central cluster of CPVT/ARVD mutations 
(CPVT-II, (George et al. 2007), http://www.fsm.it/cardmoc/) and is flanked by putative 
binding sites for the protein FKBP 12.6. Cryo-EM places this region in the clamp (Liu et al. 
2005, Wang et al. 2011). 
3.4.4 The SPRY domains 
The SPRY domain (sp1A kinase and the ryanodine receptors) (Ponting  et al. 1997) structurally 
consists of several antiparallel -strands connected with flexible loops. The precise function of 
the SPRY domain (and the related B30.2 domain) is unknown; however, it is believed to act as 
a protein–protein interaction module capable of binding multiple targets by recognizing the 
conformation of a partner protein rather than a consensus sequence motif (Woo et al. 2006, Yao 
et al. 2006). The B30.2/SPRY domain has been identified in numerous and diverse proteins 
across bacterial and eukaryotic species (e.g. pyrin/marenostrin and other butyrophilin-like 
homologues, ryanodine receptors and midin1), including over 150 proteins in humans 
(Rhodes et al. 2005), suggesting that the specific function of the B30.2/SPRY domain within a 
given protein may heavily rely on the other domains in their neighbourhood (Kleiber and 
Singh 2009). PFAM predicted that RyR2 contains three SPRY domains, corresponding to 
residues 670–808, 1098–1221, and 1433–1561. The first two domains contain three 
CPVT/ARVD mutations: R739H, T1107M and A1136V (Medeiros-Domingo et al. 2009), Fig. 2, 
which lie outside of the four mutation clusters. 
3.4.5 The RyR domains 
Four copies of the RyR domain are present in the ryanodine receptor, of which two belong 
to the N-terminal and two to the central regions. The function of this domain is unknown 
(Ponting 2000). In the second RyR domain, two isolated CPVT mutations, which lie outside 
of the four mutation clusters, have been found to date: R1013Q and R1051P, Fig. 2 
(Marjamaa et al. 2009, Medeiros-Domingo et al. 2009). 
3.4.6 The RIH_associated and RR_TM4-6 domains 
According to PFAM, the RIH_associated domain should lie between residues 3465–3960. 
This domain contains the calmodulin binding site, which was localized to the column region 
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of RyR according to cryo-EM (Samso and Wagenknecht 2002). The adjacent RR_TM4-6 
domain was predicted to lie between residues 4333–4599 by PFAM. It contains the divergent 
region DR1 (Liu et al. 2002), the putative calcium sensor that is responsible for the 
physiological activation of RyR2 (Chen et al. 1998, Li and Chen 2001), and also the 
calmodulin-like domain (Xiong et al. 2006). The end of the RIH_associated domain together 
with the RR_TM4-6 domain (aa. 3722–4610) were identified as a separate functional domain 
(called the I-domain) (George et al. 2004), which contains a third cluster of CPVT/ARVD 
mutations (CPVT-III, (George et al. 2007), http://www.fsm.it/cardmoc/); cryo-EM locates 
this domain in the column of RyR1 (Wang et al. 2011). 
3.4.7 The Ion_Trans domain 
The Ion_Trans (ion transport) domain covers the transmembrane region of the ryanodine 
receptor. This domain is found in most voltage-dependent ion channels as well as in RyRs 
and IP3Rs. The domain usually has six transmembrane helices, the final two of which flank 
a loop that determines ion selectivity (Unnerstale et al. 2009). The tetrameric ion channels 
(potassium channels, IP3Rs and RyRs) contain one Ion_Trans domain per monomer, while 
the sodium and calcium channels contain four Ion_Trans domain repeats. This domain is 
located in the transmembrane region, embedded in the membrane of the SR, Fig. 1A,B, and 
contains the ion conducting pore. It has been proposed that the pore includes the 
GVRAGGGIGD amino acid sequence (Du et al. 2001, Zhao et al. 1999), where the amino 
acids GGIG were proposed to form a selectivity filter (Balshaw et al. 1999, Gao et al. 2000). 
The fourth cluster of CPVT/ARVD2 mutations (CPVT-IV, (George et al. 2007), 
http://www.fsm.it/cardmoc/) occurs in this domain and in the flanking regions on both its 
sides.  
3.4.8 Regions without a known domain structure  
Two of the three regions of isoform sequence diversity (DR2 and DR3; (Perez et al. 2003, 
Zhang et al. 2003)) are located outside of the PFAM-predicted domains. DR2 is located 
between the second and the third SPRY domains (residues 1353-1397, Liu et al. 2004), while 
DR3 (residues 1852-1890) is located between SPRY3 and RIH2. Both DR2 and DR3 are found 
in the clamp region of RyR1 (Wang et al. 2011). DR3 contains two isolated CPVT/ARVD2 
mutations, G1885E and G1886S (Milting et al. 2006), which lie outside of the four mutation 
clusters. 
The second and third leucine-isoleucine zipper (aa. 1604–1644 and 3004–3041), that were 
found to bind PP2A and PKA with the help of the adapter proteins PR130 and mAKAP, 
respectively (Marx et al. 2001), are also located outside the PFAM-predicted domains. The 
location of these motifs in the 3D structure of the RyR2 is unknown. 
4. Cloning, expression and characterization of predicted N-terminal hRyR2 
domains 
In our previous work we concentrated on the production and characterization of 
recombinant N-terminal domains of hRyR2 (residues 1–759) in Escherichia coli expression 
systems ((Bauerova-Hlinkova et al. 2010); unpublished results). Based on the bioinformatics 
analysis described above, we assumed that the predicted domains would form individual 
entities and might behave as stable proteins. We designed several constructs covering the 
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predicted first three N-terminal domains (Ins145_P3_rec, MIR, RIH) with various starting 
and terminating residues, Table 1, taking into consideration the predicted secondary 
structure elements and the known structure of the related IP3R domains. All fragments were 
designed not to disrupt the predicted secondary structure elements, Fig. 6. In this study we 
obtained three authentic recombinant hRyR2 fragments with good expression yields and 
solubility: 1–606 (involves first three putative N-terminal domains), 391–606 and 409–606 
(involves the core of the predicted RIH domain) and several hRyR2 fragments expressed 
with a fusion partner, either thioredoxin or Nus A protein, Table 1.  
 
hRyR2 fragment Calculated Mw  103 Protein Expression 
1–247.His6 27.9 ++ 
1–606.His6 68.6 ++ 
391–606.His6 25.2 ++ 
409–606.His6 23.2 +++ 
Nus.1–606 128.6 ++ 
Nus.230–606 104.0 ++ 
Trx.384–606.His6 43.3 +++ 
Trx.391–606.His6 42.5 +++ 
Trx.409–606.His6 40.5 +++ 
Table 1. Designed fragments of the N-terminal part of hRyR2 with good expression and 
solubility. The fragment 1–247.His6 contains the Ins145_P3_rec domain. The longest N-
terminal hRyR2 fragment 1–606.His6 involves all three putative N-terminal domains. The 
hRyR fragments 384–606, 391–606 and 409–606 involve the core of the RIH domain. To 
improve solubility, some fragments were expressed with fusion partners – Nus A protein 
and thioredoxin.  Quantification of expression: ++ 1–5 mg/g expressed cells, +++ more than 
5 mg/g expressed cells. The amount of the protein was determined after IMAC purification 
(Bauerova-Hlinkova et al. 2010).  
The folding and thermal stability of these expressed fragments was assessed by circular 
dichroism (CD) spectroscopy (Fig. 4) and a thermofluor shift assay (Fig. 5). The secondary 
structure content of the fragments was derived from the CD spectra using the CDsstr 
algorithm (Johnson 1999) with an extensive set of reference databases (Whitmore and 
Wallace 2004). For the longest fragment, 1–606, the amount of -helices and -strands 
resulted in ca. 23 and 29%, respectively (Fig. 4A; (Bauerova-Hlinkova et al. 2010). For the C-
terminal domain covering residues 409 to 606 (Fig. 4B), a higher degree of -helicity (ca. 
50%) was found. This value is lower than expected from the model for this region (62%, see 
section 4.1.), which indicates that the expected N-terminal helix might be only partially 
folded. Such disorder within the terminal regions is frequently observed in NMR and X-ray 
derived structures of protein fragments. The spectra of the thioredoxin fusion protein 
fragments 384–606 (Fig. 4C) and 409–606 (Fig. 4D) indicated -helix and β-strand contents of 
ca. 40 and 10%, respectively.  
With temperature increasing up to 35°C, only small changes of the CD signal could be 
observed for fragment 1–606 (Fig. 5A), but further heating resulted in irreversible 
precipitation under our experimental conditions (Bauerova-Hlinkova et al. 2010). A similar 
behaviour was observed for the fragment 409–606, which was stable up to 37°C (Fig. 4B) and 
started to precipitate at T > 42°C (data not shown). When the fragment 409–606 was fused 
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with thioredoxin A, its CD signal indicated a gradual loss of α-helicity (ca. 25% at 95°C) that 
was fully recovered upon cooling (data not shown). 
 
 
 
Fig. 4. Far-UV CD spectra of recombinant hRyR2 fragments 1–606 (A) and 409-606 (B), and 
as fusion proteins with thioredoxin A at the N-terminus Trx-384-606 (C) and Trx-409-606 
(D). Spectra were recorded in an 0.02-cm cell at 4°C (solid line) and 37°C  (dashed line; 35°C 
for hRyR2 1–606). Samples were dialyzed into 100 mM NaF, 20 mM Tris SO4 pH 7.5 or 8.0, 
including either 0.1% Tween-20 (A-C) or sulfobetaine SB14 (D). Deconvolution of the 4°C 
spectra using the CDsstr algorithm as implemented in Dichroweb with various reference 
databases ((Whitmore and Wallace 2004); http://dichroweb.cryst.bbk.ac.uk/) results in the 
amount of -helix and β-strand shown at the top right of each panel. 
The results of the thermofluor shift assay, performed with the longest hRyR2 fragment 1–
606, were in good agreement with the temperature dependence of the circular dichroism 
spectra. The thermal stability of the fragment was tested in a wide range of buffers (Tris, 
Hepes, MES, citrate, Na/K phosphate, Bicine, Tricine; pH range 5.0–9.0), Fig. 5, and in the 
presence or absence of 1 and 5 mM Ca2+, Mg2+, ATP and 5–20% glycerol. The fragment is the 
most stable in neutral-basic pH (7.0–8.0) with a Tm of ~45°C, Fig. 5B, C. The presence of Ca2+ 
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or ATP did not change the Tm significantly, suggesting that the fragment does not contain 
binding sites for these ligands. 
 
 
Fig. 5. The first derivative of the thermal denaturation curve of recombinant 1–606 hRyR2 
fragment obtained by thermofluor shift assay, measured in 200 mM Na-citrate, pH 5.5 (A), 
and 200 mM Na-phosphate, pH 7.5 (B).  C. Tm of the recombinant hRyR2 fragment 1-606 
obtained by the thermofluor shift assay in  different buffers and pH (1 – K-phosphate 5.0; 2 – 
Na-phosphate 5.5; 3 – Na-citrate 5.5; 4 – MES 5.8; 5 – K-phosphate 6.0; 6 – MES 6.2; 7 – Na-
phosphate 6.5; 8 – Na-cacodylate 6.5; 9 – MES 6.5; 10 – K-phosphate 7.0; 11 – HEPES 7.0; 12 – 
Na-acetate 7.3; 13 – Na-phosphate 7.5; 14 – Tris 7.5; 15 – Imidazol 8.0; 16 – HEPES 8.0; 17 – 
Tris 8.0; 18 – Bicine 8.0; 19 – Tris 8.5; 20 – Bicine 9.0). The conditions under which RyR2 1–
606 was the most stable are in red. For each measurement 8 g of protein were used.  
4.1 Model structure of the N-terminal part of hRyR2 
The amino-acid sequence of the recently determined structure of the N-terminal region of 
rabbit RyR1 (PDB ID 2XOA (Tung et al. 2010)) is 63% identical and 77% similar to the 
corresponding sequence of hRyR2 (similarity is here defined as having a Gonnet Pam250 
matrix score > 0.5 as determined by ClustalX 2.1). The 2XOA structure therefore represents 
an excellent template for constructing a homology model of the N-terminal region of hRyR2. 
The structure covers residues 12–543 of the hRyR2 sequence. The homology model was 
constructed using Modeller 9v8 (Sali and Blundell 1993). The hRyR2 sequence was first 
aligned with the template structure using the alignment.align2d command of Modeller and 
then manually edited to improve the alignment (Fig. 6). This alignment was used to build a 
homology model using the automodel class. Residues 90–107 of the human sequence, which 
had been disordered in the template structure, were constrained to form an -helix in 
accordance with the secondary structure predictions, see below. The structure was 
thoroughly refined using automodel.library_schedule = autosched.slow and 
automodel.max_var_iterations = 300 for the initial optimization step, which was then 
followed by molecular dynamics refinement using automodel.md_level = refine.slow. The 
whole process was repeated twice. The refinement target function (objective function) 
minimized the geometry restraints and Charmm energy terms enforcing proper 
stereochemistry (described in (Sali and Blundell 1993)). 
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Fig. 6. The sequence alignment of hRyR2 and rabbit RyR1 (PDB ID 2XOA) sequences which 
was used as a template for the homology modeling of the hRyR2 tertiary structure. The 
alignment was performed using the alignment.align2d command of Modeller 9v8 (Sali and 
Blundell 1993). The secondary structure elements of hRyR2 (-helices and β-strands are 
shown as red bars and blue arrows, respectively) were predicted by Jpred (Cole et al. 2008). 
The numbering of predicted secondary structure elements of hRyR2 corresponds to those 
found in the RyR1 template structure (-helices and β-strands are shown as pink bars and 
light blue arrows, respectively). The alignment covers residues 1–543 of the human RyR2 
protein. Residues in grey are missing in the RyR1 structure and correspond to flexible loops. 
Identical residues (~64%) in both sequences are labelled by asterisks. 
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Twenty trial structures were generated and the best one was chosen by first discarding all 
those with unreasonable geometry in the loop regions, and then selecting the one with the 
lowest objective function score.  The loops in this structure were then refined using the 
functions found in the Modeller loopmodel class (described in Fiser et al. (2000)). This was 
done in two stages. First, the loop containing helix 1A (see below) was refined to give five 
different positions. Second, for each of these positions an additional five structures were 
generated with different positions for all of the loops. The final structure was selected based 
on the lowest objective function. The final structure was inserted into the RyR1 crystal 
packing arrangement to check for possible clashes with neighbouring molecules, which 
might indicate unlikely loop conformations; none were found. The final model is shown in 
Fig. 7A,B. 
The hRyR2 model contains three domains, aa. 12–219 (Ins145_P3_rec), 228–408 (MIR) and 
411–543 (RIH; residue numbers refer to the hRyR2), analogous to those of the template 
structure (Tung et al. 2010). The RyR1 template structure and hRyR2 homology model are in 
agreement with the PFAM predictions shown in Fig. 2; however, the beginning of the third 
domain, RIH, is shifted by about 40 aa. residues towards the N-terminus.  
With a few exceptions, the hRyR2 homology model (Fig. 7) confirmed the secondary structure 
predictions, nearly all of the -strands (22 out of 27) were found in the predicted positions in 
the template structure, although with a minor shift of one to three residues, Fig. 6. 
 
 
Fig. 7. (A) hRyR2 homology model constructed by Modeller 9v8 (Sali and Blundell 1993) 
using the alignment with rabbit RyR1, shown in Fig. 6. Loops which were disordered in the 
template structure and the modelled 1A-helix are in orange. Residues which cause 
physiological dysfunction of hRyR2 when mutated are indicated. (B) The RyR2 homology 
model coloured according to the domains predicted using the PFAM database. The colour 
scheme is the same as in Fig. 2; Ins145_P3_rec is green, MIR is red, and RIH is yellow. The 
grey -helix, 2 (aa. 409–436), according to the PFAM results, precedes the RIH domain, but 
is not part of the MIR domain.  
The beginning of the first -strand (1A; aa. 11–16) was missing in the template structure so 
that its presence could not be verified. The short -strands 5A, 9A, and 13A were not 
present in the RyR1 structure. 23 was present in the template and the modelled structure 
but was not predicted by JPred. Three long -helices (2, 3, and 6) were correctly 
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predicted by JPred with small variations at the beginnings or the ends in the model. In the 
region of the predicted helix 4, two shorter -helices were modelled which are separated 
from each other only by a two-residue turn, as found in the template structure. Neither the 
shortest -helix (aa. 325–328) nor four out of the five 310 helices were predicted.  
The first predicted -helix (1) deserves additional consideration. In comparison to RyR1, the 
RyR2 sequence contains a 12-residue insertion, Fig. 6, suggesting that the structure of this 
region differs in these two proteins. In hRyR2, helix 1 was predicted to be 33 residues long 
(residues 75–107). However, the Ins145_P3_rec domain, which includes the helix 1, was 
determined independently three times in RyR2 and contains only the first ten residues of this 
helix, followed by a gap (Lobo and Van Petegem 2009). This indicates that the predicted helix 
1 cannot span the whole range. Instead, most likely, this region forms a helix-turn-helix motif 
(aa. 75–110), as found in the structure of the IP3R ligand binding suppressor domain (Bosanac 
et al. 2005). The motif has to be rather flexible to explain its absence in the previously solved 
RyR structures as well as the conformational flexibility predicted by (Bosanac et al. 2005). 
Inclusion of an 18-residue 1A, separated from the helix 1 observed in the template structure 
by a six-residue linker, resulted in five different conformations, which shows that the 
modelled motif has sufficient mobility to explain its absence in the solved structures. Most 
likely, this motif will be stabilized in the whole RyR2 protein by interaction with a binding 
partner (another RyR2 domain or an interacting ligand).  
Between the helix 1A and the long disordered loop containing residues 464–477, there is a 
very large cavity, which suggests the existence of a large binding pocket. The helix 1A and 
the loop 464–477, which sit atop of this cavity, both contain several aromatic residues (W98, 
F100, H469, H472). The presence of the aromatic residues in the surface, three of which are 
exposed to the cavity (F100, H469, H472) may indicate protein-protein binding events with a 
putative ligand. The P466A mutant, located at the beginning of the loop, is known to 
substantially disrupt the proper physiological function of RyR2, causing syncope (Tester et 
al. 2005). Proline residues have lower conformational flexibility than other residues, so the 
most likely reason for the importance of P466 would be a necessity to decrease the flexibility 
of the loop containing residues 464–477. In addition to the P466A mutant, two other mutants 
in this area are also known to cause RyR2 dysfunction: A77V, causing CPVT and ARVD2 
(d'Amati et al. 2005), and V186M, causing CPVT (Tester et al. 2006). All three mutations in 
this area induce only small changes in the surface shape of the protein. Taken together, all 
this implies that this part of the structure might be involved in the binding of RyR2 to other 
interacting proteins or its own domains. This is consistent with the results seen in RyR1, 
where the docking of the first three N-terminal domains into the full-length cryo-EM density 
map revealed that the loop involving P455 (P466 in hRyR2) as well as the beginning of helix 
4 belong to interface 6 (Tung et al. 2010). 
The reliability of the hRyR2 homology model is further confirmed by the CD-spectroscopy 
of hRyR2 fragment 1–606, Fig. 4A, which revealed 23% -helices and 29% β-strands in the 
fragment. This is in good agreement with the hRyR2 model structure, in which the content 
of -helices and β-strands was 23% and 24%, respectively.  
5. Conclusion 
In this work, bioinformatics analysis of the whole human RyR2 is presented. The analysis 
shows that the protein is composed of 14 domains. We were concerned particularly with the 
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first three N-terminal domains of the protein (Ins145_P3_rec, MIR, RIH). Verification that 
the domains identified can behave as separate, independent protein units was provided by 
their successful expression in E. coli and subsequent characterization. CD-spectroscopy was 
used to determine the domain organization and to identify the secondary structure elements 
of the N-terminal part of hRyR2. The amino acid sequence identity of hRyR2 with that of 
rabbit RyR1, the X-ray structure of which is known, is higher than 60%, which allowed the 
construction of a reliable homology model of the N-terminal part of hRyR2. Its reliability 
was further strengthened by its conformity with the bioinformatics analysis and the CD-
spectroscopy study. This model should allow a clearer insight to be gained into the possible 
influence of mutations on the cardiac diseases CPVT1 and ARVD2. 
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